Ultra Sound Guided Fine Needle Aspiration Cytology (FNAC) of Liver and Pancreas Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00991601
Recruitment Status : Suspended (New ultra sound technology have made this present study design less relevant and force us to change the design of the study.)
First Posted : October 8, 2009
Last Update Posted : October 13, 2010
Information provided by:
Herlev Hospital

Brief Summary:
Patients with tumors in liver or pancreas are randomized to ultrasound (UL)-guided FNAC biopsies with guidance method or UL-guided FNAC biopsies with free-hand method.

Condition or disease Intervention/treatment Phase
Tumors in Liver Tumors in Pancreas Procedure: FNAC (fine needle aspiration cytology) Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Study Start Date : July 2009
Estimated Primary Completion Date : September 2011
Estimated Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy
U.S. FDA Resources

Arm Intervention/treatment
Experimental: biopsy arm
patients with tumors in liver and/or pancreas
Procedure: FNAC (fine needle aspiration cytology)
UL guided biopsy

Primary Outcome Measures :
  1. quality of obtained biopsy [ Time Frame: one year ]

Secondary Outcome Measures :
  1. patients pain and discomfort at procedure [ Time Frame: immediately ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult over 18 years
  • tumors in liver and/or pancreas

Exclusion Criteria:

  • low coagulation factors
  • mentally ill patients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00991601

Herlev Hospital
DK-2730, Herlev, Herlev, Denmark, 2730
Sponsors and Collaborators
Herlev Hospital
Principal Investigator: Jakob Burcharth, MD Herlev Hospital
Study Director: Bjørn Skjoldbye, MD Herlev Hospital

Responsible Party: Jakob Burcharth, MD., Herlev Hospital, Department of surgical Gastroenterology Identifier: NCT00991601     History of Changes
Other Study ID Numbers: H-KA-05092
First Posted: October 8, 2009    Key Record Dates
Last Update Posted: October 13, 2010
Last Verified: October 2010

Keywords provided by Herlev Hospital:

Additional relevant MeSH terms:
Gastrointestinal Agents